Oncology Medical News about non-Hodgkin lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical outcome in patients with small intestinal non-Hodgkin lymphoma
Leukemia and Lymphoma, 10/30/09

Kako S et al. – The role of surgery in small intestinal lymphoma remains equivocal. In the current study, surgery before other therapies favorably influenced FFS, and all patients who underwent complete resection of the small intestinal lesion had extremely favorable results. Further studies are warranted to establish optimal therapeutic strategies.

<< Previous
MACOP-B regimen in the treatment of adult Langerhans cell...

Next >>
Increasing incidence rates of soft tissue sarcomas? A...

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09 Relevance Score: 68%

Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkins lymphoma: The Iowa Womens Health Study
International Journal of Cancer, 11/05/09 Relevance Score: 67%

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
Cancer Management and Research, 10/23/09 Relevance Score: 67%

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study : The Lancet Oncology
The Lancet Oncology - Online First, 10/12/09 Relevance Score: 67%

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Journal of Clinical Oncology, 10/08/09 Relevance Score: 67%